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Plasmacytoid dendritic cells (pDC) are specialized in massive production of type I
interferons (IFN) upon viral infections. Activation of IFN regulatory factor (IRF)-7 is
critically required for the synthesis of type I IFN in pDC. IRF-7 is highly expressed by
resting pDC and translocates into the nucleus to initiate type I IFN transcription. In a
previous work, we observed an impaired IFN-a production in enriched cord blood pDC
following a TLR9 stimulation using CpG oligonucleotides. Herein, we show that highly
purified pDC from cord blood exhibit a profound defect in their capacity to produce
IFN-a/b in response to TLR9 as well as to TLR7 ligation or human CMV or HSV-1
exposure. Microarray experiments indicate that expression of the majority of type I IFN
subtypes induced by a TLR7 agonist is reduced in cord blood pDC. We next
demonstrated a reduced nuclear translocation of IRF-7 in cord blood pDC following
CpG and HSV stimulation as compared to adult pDC. We conclude that impaired IRF-7
translocation in cord blood pDC is associated with defective expression of type I IFN
genes. Our data provide a molecular understanding for the decreased ability of cord
blood pDC to produce type I IFN upon viral stimulation.
Supporting information for this article is available
at http://www.wiley-vch.de/contents/jc_2040/2008/37760_s.pdf
Introduction
Production of type I interferons (IFN) is a key feature of
the host defense against invading pathogens. In addition
to their anti-viral activities, type I IFN strongly activate
both innate and adaptative immunity [1]. Although
most cell types can produce type I IFN, plasmacytoid
dendritic cells (pDC) represent a major source of these
cytokines, especially upon viral infections or exposure to
ligands of Toll-like receptor 9 (TLR9) (e.g. unmethy-
lated CpG-rich deoxynucleotides) or TLR7 (e.g. resiqui-
mod (R-848)) [2, 3]. Activation of IFN regulatory factor
Correspondence: Michel Goldman, Institute for Medical Im-
munology, 8 rue Adrienne Bolland, B-6041 Charleroi-Gosselies,
Belgium
Fax: +32-2-650-95-63
e-mail: mgoldman@ulb.ac.be
Received 16/8/07
Revised 16/10/07
Accepted 13/11/07
[DOI 10.1002/eji.200737760]
Key words:
Cord blood  Dendritic
cell  IFN-a
 Interferon regulatory
factor 7  Newborn
Abbreviations: CBMC: cord blood mononuclear cells ;
HCMV: human cytomegalovirus ; IRF: interferon regulatory
factor ; pDC: plasmacytoid dendritic cell  TRAF: TNF receptor-
associated factor
Eur. J. Immunol. 2008. 38: 507–517 Innate immunity 507
f 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
(IRF)-7 is critically required for the induction of type I
IFN synthesis in pDC [4]. Indeed, IRF-7 is highly
expressed in the cytoplasm of resting pDC and
translocates in the nucleus upon activation of pDC
[5]. Whereas type I IFN production is a key feature of
pDC, they also mature and produce several inflamma-
tory cytokines and chemokines upon TLR7/9 ligation.
This pathway has been shown to be dependent on NF-jB
activation [6, 7]. Although pDC are present in significant
numbers in human cord blood, there is evidence that
they do not function as their adult counterparts since we
found that they secrete less IFN-a upon exposure to CpG
[8].
Herein, we first specified this defect by comparing
the maturation and the production of type I IFN and
inflammatory cytokines under different conditions of
stimulation including exposure to viruses. The observa-
tion that IRF-7-dependent responses were profoundly
defective whereas NF-jB-dependent responses were
partially affected led us to compare the nuclear
translocation of IRF-7 and NF-jB in activated pDC
isolated from adult and cord blood.
Results
IFN-a/b induction through TLR7 is impaired in
cord blood pDC
Using immunomagnetic selection procedure, pDC were
purified from fresh blood obtained from human
placental cords and adult donors. This method enabled
us to obtain >95% pure pDC in both adult and cord
blood cell populations. In order to study the ability of
cord blood pDC to produce IFN-a/b in response to a
TLR7 agonist, we used resiquimod (R-848), a small
synthetic compound belonging to the family of imida-
zoquinolines. Dose-response experiments indicate that
R-848 elicited IFN-a secretion in a dose-dependent
manner with a maximal effect at 10 lg/mL of R-848,
whereas IFN-a secretion by cord blood pDC was severely
impaired whatever the dose of the stimulus used
(Fig. 1A). We confirmed these results by stimulating
pDC from a larger number of adult donors and cord
blood samples with R-848 (10 lg/mL), showing that
cord blood pDC produced significantly less IFN-a as
compared to their adult counterparts (Fig. 1B). More-
over, we quantified IFN-b production using the same
experimental conditions, showing that IFN-b levels are
significantly lower when produced by cord blood pDC
(Fig. 1C).
To determine whether the neonatal defect in type I
IFN production was already apparent at the mRNA level,
we used real-time RT-PCR to measure IFN-a2 and IFN-b
gene expression in R-848-stimulated cord blood and
Figure 1. Defective IFN-a/b synthesis in R-848-stimulated cord
blood pDC. (A) Purified pDC (2105 cells/mL) were cultured
with graded doses of R-848, at the concentration of 2105 cells/
mL for 48 h. Supernatantswere collected and assayed by ELISA
for detection of IFN-a levels. One representative adult and cord
blood sample out of three is shown. (B, C) Adult and cord blood
pDC were stimulated with R-848 (10 lg/mL), and IFN-a (B) and
IFN-b (C) levels were quantified by ELISA. Data represent the
means  SEM of 14 adult and 14 cord blood pDC samples (B)
(***p<0.001 cord blood versus adult pDC) or six adult and cord
blood pDC samples (C) (**p<0.01 cord blood versus adult pDC).
(D, E) Adult and cord blood pDC were incubated with R-848
(10 lg/mL) for the indicated times. Total RNAwas extracted and
real-time PCR was performed for IFN-a2 and IFN-b mRNA
quantification. Results are expressed in mRNA copy numbers
per 103 b-actinmRNA copies. Themeans  SEM obtained from
three different adult and cord blood samples are shown. (F, G)
Adult and cord blood pDC were stimulated as described above
with R-848 (10 lg/mL), and IL-6 (F) and TNF-a (G) levels were
quantified by ELISA. Data represent the means  SEM of ten
adult and ten cord blood pDC samples; **p<0.01 cord blood
versus adult pDC.
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adult pDC. As shown in Fig. 1D, IFN-a2 mRNA
accumulation peaked in adult pDC at 2 h following
R-848 incubation. IFN-b mRNA accumulation followed
the same kinetics as shown in Fig. 1E. In contrast, R-848-
induced IFN-a2 and IFN-b expression was severely
decreased in cord blood pDC at any time point.
As R-848 also induces inflammatory cytokine
production in pDC, we thus evaluated TNF-a and IL-6
secretion by adult and cord blood pDC using the same
experimental conditions. As shown in Fig. 1F, IL-6
synthesis was comparable between adult and cord blood
pDC following R-848 stimulation. On the other hand,
cord blood pDC produced significantly lower levels of
TNF-a than adult pDC in response to R-848 (Fig. 1G).
Cord blood pDC exhibit a reduced maturation in
response to TLR7 ligation
In parallel to cytokine production analysis, we compared
the phenotypical changes induced by R-848 on adult
versus cord blood pDC. For this purpose, we stimulated
adult and cord blood purified pDC with R-848 (10 lg/
mL) for 24 h. Cells were collected and stained for cell
surface molecules and their expression was analyzed by
flow cytometry. As shown in Fig. 2, apart from CD86
marker, R-848 indeed induced a clear up-regulation of
CD80, CD40, CCR7, CD54 and HLA-DR molecules on
adult pDC. Cord blood pDC also responded to R-848, as
all markers of maturation tested were up-regulated
compared to resting pDC. However, the magnitude of
CD80, CD40, CCR7 and HLA-DR up-regulation was
significantly lower in cord blood pDC. In contrast, CD54
and CD86 expression in R-848-stimulated pDC did not
differ between neonatal and adult cells. Taken together,
these data reveal that the defect of cord blood pDC in
response to R-848 is not limited to type I IFN production
but also involves, albeit to a lower degree, the
acquisition of a mature phenotype and the production
of TNF-a.
Expression of type I and type III IFN subtypes is
decreased in R-848-stimulated cord blood pDC
To get a broader overview of the TLR7-mediated
responses in cord blood pDC, we compared the gene
expression profile induced by R-848 in adult and cord
blood pDC using oligonucleotide microarray technique.
Adult and cord blood pDC were stimulated for 2 h with
R-848 (10 lg/mL), a time point which corresponds to
the peak of IFN-a/b mRNA induction, as previously
shown. Thereafter, RNA samples were hybridized to
microarrays designed to detect 54676 transcripts.
Our analysis indicates first that 1055 genes were
significantly up-regulated in adult pDC in response to
R-848 and among them, 256 were found to be
significantly differentially regulated between adult
and cord blood pDC (Supporting Information Table 1).
We next compared in adult pDC versus cord blood pDC
stimulated with R-848, expression of IRF-7-dependent
genes, such as type I and type III IFN subtypes, and of
NF-jB-dependent genes, like IL-6 and TNF-a genes.
Table 1 clearly shows that type I and type III IFN
family subtypes were all induced upon TLR7 triggering
by adult pDC. All of these genes were significantly less
up-regulated in cord blood pDC. Indeed, the ratio of the
fold change (fold change adult pDC/fold change cord
blood pDC) ranged from 4.3 to 45.1. The decreased
expression of IFN-a2 and IFN-b genes in R-848-
Figure 2. Incompletematuration of cord blood pDC in response
to R-848. Adult and cord blood pDC were incubated with R-848
(10 lg/mL) for 24 h. Cells were harvested and analyzed by flow
cytometry after staining with the indicated mAb. Data are
expressed as the means of MFI  SEM obtained from eight
different adult and cord blood samples; *p<0.05, **p<0.01 cord
blood versus adult pDC.
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stimulated cord blood pDC was thus also apparent in the
microarray analysis.
In Table 2 we compared the expression of 18 NF-jB-
inducible genes in adult and cord blood stimulated pDC.
Among them, only five genes were found to be
significantly differentially expressed between adult
and cord blood pDC whereas the ratio of the fold
change from 13 of those genes ranged from 0.87 to 1.92
(Table 2). Of note, IL-6 and TNF-a gene induction in
cord blood pDC was in agreement with our observations
presented in Fig. 1F, G. Indeed, IL-6 production was
found to be comparable between adult and neonatal
pDC whereas TNF-a production was found to be
significantly lower in cord blood pDC. Overall, these
data revealed a profound defect in the expression of
type I and type III IFN family subtypes in R-848-
stimulated cord blood pDC whereas NF-jB-dependent
responses were less affected.
CpG-induced IFN-a/b production is impaired in
cord blood pDC
In a previous work, we observed an impaired IFN-a
production in enriched cord blood pDC following a TLR9
stimulation using CpG oligonucleotides [8]. Herein, we
first confirmed that highly purified cord blood pDC were
impaired in their capacity to mount significant IFN-a
response whatever the dose of CpG A used for their
stimulation (Supporting Information Fig. 1). We next
extended our findings to IFN-b production upon
stimulation with CpG A (10 lg/mL) and we observed
that IFN-b levels were also significantly lower in
supernatants of activated cord blood pDC as compared
to adult pDC (Fig. 3A). In the same time, we measured
IFN-a2 and IFN-b mRNA accumulation in cord blood
and adult pDC upon CpG stimulation (10 lg/mL). We
could observe that IFN-a2 and IFN-b mRNA levels
peaked 8 h following TLR9 ligation in adult pDC. In
contrast, expression of IFN-a2 and IFN-b genes was
profoundly decreased in cord blood pDC at any time
point of the kinetic (Fig. 3B, C). Altogether, these data
establish that type I IFN induction through TLR7 and
TLR9 is impaired in cord blood pDC.
Nuclear translocation of IRF-7 is defective in
response to CpG stimulation in cord blood pDC
The findings that TLR7- and TLR9-dependent responses
developed by cord blood pDC were defective led us to
analyze TLR7/9 expression in adult and neonatal pDC at
the basal level. As assessed by real-time RT-PCR shown
in Fig. 4A, TLR7 and TLR9mRNA levels were found to be
Table 1. List of type I and type III IFN genes in adult pDC versus neonatal pDC
Gene Fold change adultsa) Fold change newborns Ratio fold change adults/newborns
IFN-a8 125.73 2.80 45.10
IFN-a1 666.01 20.86 31.93
IFN-x1 213.76 9.10 23.60
IFN-a7 264.49 14.46 18.30
IFN-a10 489.92 27.07 18.10
IFN-a21 150.59 8.33 18.07
IFN-a4 369.82 20.64 17.92
IFN-a17 116.72 6.60 17.80
IFN-a5 656.74 41.79 15.71
IFN-a13 132.69 9.59 13.83
IFN-k2 174.44 13.02 13.40
IFN-a16 842.47 66.26 12.71
IFN-k3 60.77 5.90 10.30
IFN-a14 621.03 79.46 7.82
IFN-a6 8.61 1.30 6.70
IFN-a2 1203.34 185.98 6.47
IFN-b1, fibroblast 1136.57 263.03 4.32
IFN-k1 10.86 2.50 4.30
a) Gene expression is described as themean of the fold change (ratio between treated and untreated pDC) of three donors in each
group.
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comparable between resting adult and cord blood pDC.
Therefore, the defective IFN-a/b production by cord
blood pDC could not be attributed to a lower expression
of TLR7 and TLR9.
Upon TLR7/9 signalling, IRF-7 becomes phosphory-
lated and then translocates into the nucleus where it can
activate type I IFN genes. We first analyzed the basal
expression of IRF-7. IRF-7 mRNA levels, assessed by real-
time RT-PCR, and IRF-7 protein levels, measured by
intracellular cytoplasmic staining technique, were
comparable in both adult and cord blood pDC
(Fig. 4B, C). Furthermore, the basal expression of
several molecules implicated in the TLR7/9 signalling
pathway such as MyD88, TNF receptor-associated factor
(TRAF)6, IRAK4 and IRAK1 was comparable between
resting adult and cord blood pDC as assessed by the
microarray analysis (Supporting Information Table 2).
To quantify nuclear translocation of IRF-7 in
activated pDC, we used the ImageStream technology
developed by Amnis Corporation. This technique
combines high-resolution digital imaging with flow
cytometry technology, enabling quantitative image-
based analysis of nuclear translocation in rare sub-
populations [9].
BDCA-2/4+ cells with high IRF-7/DRAQ5 similarity
scores were gated to quantify the percentage of cells
with nuclear-localized IRF-7. Fig. 4D shows the kinetics
of the nuclear translocation of IRF-7 in pDC following
CpG incubation. We observed that the highest percen-
tage of adult pDC showing a nuclear localization of IRF-7
was reached after 6 h of stimulation. In contrast, IRF-7
nuclear translocation was not induced in cord blood
pDC upon CpG stimulation at any time point tested.
We next compared adult and cord blood samples
following 6 h of incubation with CpG A. The results
presented in Fig. 4E are expressed as fold changes of
percentage of translocated cells, calculated as ratios
between percentage of translocated cells in treated
versus untreated pDC. Our data indicate that themean of
the fold changes was 3.3 after CpG treatment in adult
pDC versus 1.3 for cord blood pDC. In those conditions,
IRF-7 nuclear translocation was significantly reduced in
cord blood pDC as compared to their adult counterparts
(Fig. 4E). Of note, we did not observe IRF-7 nuclear
translocation in response to R-848 using the Image-
Stream technique.
We also used this technique to quantify the nuclear
translocation of NF-jB in pDC following CpG stimula-
tion. Indeed, this transcription factor has been shown to
Table 2. List of 20 representative NF-jB-dependent genes in adult pDC versus neonatal pDC
Gene Fold change adultsa) Fold change newborns Ratio fold change adults/newborns
TNF 58.85 25.93 2.27b)
NF-jB2 (p49/p100) 6.93 3.13 2.21b)
Jun-B proto-oncogene 4.43 2.05 2.16b)
TRAF1 28.42 13.40 2.12b)
CCL5 11.72 5.68 2.06b)
Bcl2-related protein A1 559.73 291.18 1.92
NF-jBIA 5.95 4.41 1.35
IL-6 39.38 29.90 1.32
NGFI-A-binding protein 1 7.01 5.39 1.30
IL-1a 7.62 6.03 1.26
IL-8 209.75 176.61 1.19
CCL3 382.36 345.41 1.11
CCL4 186.06 178.45 1.04
Bcl2-like 1 15.05 15.36 0.98
pentraxin-related gene 32.47 34.09 0.95
TNF-a-induced protein 2 9.80 10.85 0.90
CXCL 2 13.07 15.04 0.87
B-cell CLL/lymphoma 2 14.61 16.82 0.87
a) Gene expression is described as themean of the fold change (ratio between treated and untreated pDC) of three donors in each
group.
b) Gene significantly differentially regulated.
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control essential functions in human pDC, such as
induction of their maturation, survival and inflamma-
tory cytokine production. As shown in Fig. 4F, NF-jB
rapidly translocated to the nucleus in adult pDC with a
peak of translocation after 2 h of CpG treatment,
followed by a reduction in nuclear localization after
6 h. Fig. 4F shows that NF-jB translocation occurred in
CpG-stimulated cord blood pDC but appeared weaker
after 2 and 4 h of incubation as compared to adult pDC.
However, after 6 h of CpG stimulation, cord blood pDC
reached adult levels in terms of percentage of translo-
cated cells.
These results indicate that although IRF-7 is present
in resting cord blood pDC, its translocation is profoundly
compromised in response to TLR9 ligation. In contrast,
NF-jB translocation seems to be less affected in cord
blood pDC under the same conditions.
Impaired cytokine secretion and defective IRF-7
translocation in cord blood pDC exposed to
viruses
pDC have been largely described as the most potent cell
type endowed with the unique property to secrete large
amounts of type I IFN following viral invasion [6]. In
contrast to other cells types, viruses do not need to be
replication-competent to activate pDC to produce
IFN-a/b [10]. Until now, TLR are considered as the
major receptors for the initiation of type I IFN produc-
tion in pDC upon virus recognition. More particularly,
viral particles containing double-stranded DNA gen-
omes, such as HSV-1 and murine cytomegalovirus are
recognized by TLR9 [10, 11].
To investigate the ability of cord blood pDC to
produce IFN-a following virus exposure, we first
incubated pDC from one adult and one cord blood
donor with increasing doses of live human CMV
(HCMV). Fig. 5A shows that as expected, adult pDC
secreted large quantities of IFN-a following wild-type
HCMV stimulation in a dose-dependent manner. In
contrast, cord blood pDC were profoundly impaired in
their capacity to mount IFN-a production whatever the
MOI used. To confirm this result, we incubated pDC
from a larger number of adult donors and cord blood
samples with HCMVat MOI 10, showing that cord blood
pDC produced significantly less IFN-a as compared to
their adult counterparts in response to HCMV (Fig. 5B).
The defect in IFN-a production by cord blood pDC could
be observed at any time of our kinetics, between 24 and
72 h (data not shown).
Furthermore, similar dose-response experiments
were performed with live HSV-1, a double-stranded
DNAvirus. As shown in Fig. 5C, live HSV-1 induced large
amounts of IFN-a in adult pDC whereas IFN-a levels
were significantly reduced from cord blood pDC for each
MOI. Our data indicate that cord blood pDC are thus
profoundly defective in IFN-a production upon HCMV
and HSV-1 exposure. We also compared TNF-a produc-
tion by adult and cord blood pDC and we could observe
that cord blood pDC produce less TNF-a after HSV-1
exposure (Fig. 5D).
We next analyzed nuclear translocation of IRF-7 in
response to HSV-1 using the ImageStream technology as
described as above [9] (Supporting Information Fig. 2).
The kinetic study of the nuclear translocation following
HSV-1 incubation indicated that the highest percentage
of adult pDC showing a nuclear localization of IRF-7 was
reached after 6 h of stimulation (Fig. 5E). In contrast,
IRF-7 nuclear translocation was not induced in cord
blood pDC upon HSV-1 stimulation at any time of the
kinetics. The analysis of a larger number of samples
indicates that the mean of the fold changes for IRF-7
translocation in adult pDC reached the value of 1.9 after
Figure 3. Impaired type I IFN synthesis in CpG-stimulated cord
blood pDC. (A) Purified pDC (2105 cells/mL) were stimulated
with CpG A (10 lg/mL), and IFN-b levels were quantified by
ELISA. Data represent the means  SEM of six adult and six
cord blood pDC samples; **p<0.01 cord blood versus adult pDC.
(B, C) Adult and cord blood pDC were incubated with CpG A
(10 lg/mL) for the indicated times. Total RNAwas extracted and
real-time PCR was performed for IFN-a2 and IFN-b mRNA
quantification. Results are expressed in mRNA copy numbers
per 103 b-actinmRNA copies. Themeans  SEM obtained from
three different adult and three cord blood samples are shown
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HSV-1 incubation whereas it was 1.1 for cord blood pDC
in the same conditions (Fig. 5F). IRF-7 nuclear
translocation in cord blood pDC was significantly
impaired as compared to their adult counterparts
following HSV-1 treatment. Our results thus show that
nuclear translocation of the transcription factor IRF-7 is
reduced in cord blood pDC after TLR9 ligation as well as
after HSV-1 exposure.
Discussion
Human newborns are more susceptible than adults to
infections with viruses, including human immunodefi-
ciency virus, respiratory syncytial virus, HCMV and HSV
[12–15]. The immaturity of the cord blood immune
system is often proposed as the main underlying factor
for such limited anti-viral immune responses in early life
[16]. More precisely, functional alterations of
T lymphocytes and antigen-presenting cells are critically
involved in such compromised neonatal immune
responses [17, 18]. Here, we show that highly purified
pDC from cord blood exhibit a profound defect in their
capacity to produce IFN-a/b in response to TLR7/9
ligation as well as to CMVor HSV-1 exposure. This defect
is detected both at the protein and mRNA levels.
Interestingly, long-term resistance to HSV-1 could be
induced in neonatal mice following IFN-a treatment at
birth, highlighting the decisive role of IFN-a and pDC for
viral resistance in early life [19]. The fact that TLR7-
dependent type I IFN synthesis is impaired in cord blood
pDC suggests that cord blood pDC responses to single-
stranded RNA viruses would be also compromised.
Through the activation of TLR7/9, robust induction
of IFN-a/b was found to be regulated by the assembly of
a multi-component complex MyD88/IRAK1/IRAK4/
TRAF3/TRAF6 allowing direct recruitment and activa-
tion of IRF-7. After being phosphorylated by IRAK1 and
activated by TRAF6, IRF-7, which is highly expressed by
resting pDC, translocates to the nucleus to initiate
IFN-a/b transcription and thus serves as a key mediator
for transcription of IFN-a/b genes [20, 21]. Recent data
suggest that IRF-5 is also important for TLR7-dependent
induction of type I IFN [22]. On the other hand, IRF-5
nuclear translocation, together with NF-jB and MAPK
activation, is crucial for the production of inflammatory
cytokines and chemokines and the maturation of the
pDC [23]. Our results showed that TNF-a production
and phenotypical maturation are also partially affected
in cord blood pDC stimulated with R-848.
·
Figure 4. IRF-7 translocation is defective in cord blood pDC. (A)
mRNAwas extracted from resting purified adult and cord blood
pDC, reverse-transcribed and amplified by real-time PCR using
primers specific for TLR7 or TLR9.mRNA levelswere quantified
and normalized against b-actin. Data represent the
means  SEM of nine adult and nine newborn donors. (B)
IRF-7 mRNA levels from resting adult and cord blood pDC were
quantified by real-time PCR as described above andnormalized
against b-actin. The means  SEM obtained from eight adult
donors and eight newborn samples are shown. (C) Untreated
PBMC or CBMC were stained for intracytoplasmic IRF-7
detection and analyzed by flow cytometry. pDCwere identified
as BDCA-2/4+ cells and analyzed for their IRF-7 expression.
Scatter plot represents the mean fluorescence intensities for
each individual donor (ten adult and ten cord blood samples).
(D–F) Adult and cord blood enriched pDC were stimulated for
the indicated times with CpG A (10 lg/mL), stained as
described inMaterials and methods and run on the ImageStream
imaging cytometer. Data were analyzed to determine the
percentage of pDC with nuclear localization of IRF-7 (D, E) or
NF-jB (F) using the IRF-7/DRAQ5 or NF-jB/DRAQ5 similarity
scoring following CpG A stimulation. Kinetics of translocation
for one representative adult versus cord blood donor is shown
(D, F). Scatter plot shows the fold change of the percentage of
translocated cells, calculated as ratios between the percentage
of translocated cells in treated versus untreated pDC for each
donor after a 6-h incubation with CpG A (E). This was done for
six adult donors and six cord blood samples; **p<0.01 cord
blood versus adult pDC.
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Beside TLR, a separate nucleic acid recognition
pathway for type I IFN production during anti-viral
responses involves RNA helicases RIG-1-MDA-5 and
their adaptor IPS-1 [21]. Although the RIG-1-MDA-5-
IPS-1 signalling is essential for type I IFN production in
response to viruses by other immune cells, the implica-
tion of this pathway in type I IFN production by pDCwill
need more investigations [24]. Until now, TLR are
considered as the major receptors for the initiation of
type I IFN production in pDC upon virus recognition.
Herein, we found that the defect of IFN-a/b
production by cord blood pDC could not be attributed
to a lower expression of TLR7 and TLR9 in those cells.
Importantly enough, we demonstrate an impaired
nuclear translocation of IRF-7 in cord blood pDC
following CpG and HSV stimulation. In contrast, NF-jB
B translocation following TLR9 ligation using CpG
treatment is less affected as compared with IRF-7
translocation in cord blood pDC. This is in concordance
with our findings that NF-jB-dependent responses such
as TNF-a induction as well as CD80, CD40 and HLA-DR
up-regulation were less altered in cord blood pDC
following TLR7 ligation. The fact that NF-jB activation
was partially affected in cord blood pDC suggests that a
perturbation in the assembly of the multi-component
complex could account for our observation. Of note, we
did not detect any difference in MyD88, IRAK and TRAF
expression between adult and cord blood resting pDC.
Whether the recruitment and/or activation of critical
signalling molecules involved in IRF-7 activation is
impaired remains to be determined. Altogether, we
propose that impaired nuclear translocation of IRF-7
provides a molecular basis for deficient type I IFN
production by cord blood pDC.
IRF-3-dependent responses to lipopolysaccharide
were recently shown to be defective in cord blood cells.
Indeed, deficient IRF-3 activity in lipopolysaccharide-
stimulated cord blood monocyte-derived DC is asso-
ciated with a reduced ability to produce IFN-b, IL-12p70
and IFN-inducible chemokines [25]. We suggest that
defective IRF-3 activation in cord blood monocyte-
derived DC and impaired IRF-7 translocation in cord
blood pDC represent two key molecular signatures
underlying the immaturity of neonatal DC.
In conclusion, we suggest that deficient IRF-7
translocation in cord blood pDC blunts their ability to
elicit anti-viral responses by limiting their production of
type I IFN. This might be relevant to the increased
susceptibility of human newborns to viral infections but
also their inability to mount efficient immune responses
to vaccines. Indeed, although CpG and R-848 molecules
have been shown to display promising adjuvant
activities in adults [26, 27], the use of these TLR
agonists as neonatal vaccine adjuvants needs to be
revisited in light of the present findings. Finally,
defective IRF-7/type I IFN axis in cord blood pDC could
also have important implications for the understanding
of higher susceptibility to microbial infections encoun-
tered after cord blood cell transplantation [28, 29].
Figure 5. Impaired IFN-a production and IRF-7 translocation in
cord blood pDC exposed to viruses. (A) Purified pDC were
cultured at 2105 cells/mL with graded doses (MOI) of wild-
type HCMV. Cell-free supernatants were collected at 72 h and
IFN-a levels were assayed by ELISA. One representative adult
and cord blood sample out of three is shown for the dose
response. (B) Purified pDCwere cultured at 2105 cells/mLwith
wild-type HCMV (MOI 10). Cell-free supernatants were col-
lected at 72 h and IFN-a levels were assayed by ELISA. Scatter
plot represents the IFN-a levels of 14 adult and nine cord blood
samples. (C, D) Purified pDC (2105 cells/mL) were exposed to
HSV-1 for 24 h, and IFN-a (C) and TNF-a (D) levels were assayed
by ELISA. Data represent the means  SEM of five adult and
five cord blood samples. (E) Adult and cord blood enriched pDC
were stimulated for the indicated times with HSV-1 (MOI 1).
After viral exposure, cell samples were stained as described in
Materials and methods and run on the ImageStream machine.
Data were analyzed to determine the percentage of pDC with
nuclear localization of IRF-7 using the IRF-7/DRAQ5 similarity
score (Supporting Information Fig. 2) following HSV-1 stimula-
tion. Kinetics of translocation for one representative adult
versus cord blood donor is shown. (F) Scatter plot shows the fold
changes, calculated as ratios between the percentages of
translocated cells in treated versus untreated pDC for each
individual donor after 6 h incubation with HSV-1. This was
done for six adult donors and six cord blood samples; **p<0.01
cord blood versus adult pDC.
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Materials and methods
Blood samples
Adult fresh blood was obtained from healthy volunteers with
informed consent and umbilical cord blood samples were
collected from healthy full-term neonates at the departments
of obstetrics of four hospitals with parental agreement
(Clinique Notre Dame-Charleroi, Notre Dame de Grce-
Gosselies, CHU-Charleroi and CHU-Tivoli-La Louvire). All
procedures were approved by the ethics committee of the
faculty of medicine at the Universit Libre de Bruxelles.
pDC purification, culture and IFN-a production
PBMC and cord blood mononuclear cells (CBMC) were
obtained from the blood samples by centrifugation on
Ficoll-Hypaque (Axis-Shield PoC AS, Oslo, Norway). pDC
were isolated by MACS, first by a negative depletion using a
cocktail of antibodies (CD16, CD19, CD14, CD15, CD33, CD3
and Glycophorin-A) directly coupled to magnetic beads
(Miltenyi Biotec) passed on an LD column, followed by a
positive selection using the anti-BDCA-4-conjugated magnetic
microbeads passed over two MS columns. The purity of the
pDC fraction was checked by staining with the anti-BDCA-2-
FITC (Miltenyi Biotec) and the CD123-PE (BD Biosciences,
Erembodegem, Belgium) mAb and was >95%.
Freshly isolated pDC were cultured at 2.5105 cells/mL in
complete medium (RPMI 1640) (Biowhittaker Europe, Ver-
viers, Belgium) supplemented with 10% FCS (Biowhittaker
Europe), 2 mM L-glutamine (Life Technologies, Paisley, UK),
20 lg/mL gentamicin, 50 lM 2-mercaptoethanol and 1%
nonessential amino acids (Life Technologies), and stimulated
with resiquimod (R-848; Pharma Technologies, China) or
CpG A (2216; Tib Molbiol, Berlin, Germany)
(50-ggGGGACGATCGTCgggggG-30) for 48 h.
Viability of purified pDC after 48 h of culture in presence or
absence of TLR ligand was determined by propidium iodide
staining (10 lg/mL final concentration). In five independent
experiments, we observed that the fractions of viable cells
(mean  SD) were 59  10%, 76  10%, 60  3% for adult
pDC, and 47  8%, 68  9%, 46  10% for cord blood pDC in
untreated, R-848 or CpG A conditions, respectively.
HCMV strain TB40/E (1108 PFU/mL) was originally
provided by Z. Tabi (College of Medicine, Cardiff, UK) and
then propagated in our institute as described by Tabi et al. [30].
pDC (2.5105 cells/mL) were exposed to the virus at the
indicated MOI. After 3 h medium was replaced by fresh
medium supplemented with IL-3 (4 ng/mL; R&D Systems,
Abingdon, UK). HSV-1 strain 2931 was provided by
P. Fitzegerald-Bocarsly (Newark, NJ); pDC were exposed to
the virus for 24 h at the indicated MOI. Cell-free supernatants
were collected and stored at –20C until quantification by
ELISA for IFN-a, IFN-b (Biosource, Nivelles, Belgium), TNF-a
and IL-6 (R&D Systems, Abdingdon, UK) following manufac-
turer's instructions.
Flow cytometry
For immunophenotyping analysis, pDC were membrane-
stained during 20 min at 4C with the following conjugated
antibodies: anti-CD80-FITC, anti-CD86-FITC, anti-CD40-PE,
anti-HLA-DR-FITC, anti-CD54-PE and anti-CCR7-PE (BD
Biosciences). Intracellular staining of IRF-7 was done as
described before [5] with the following modifications: fixation
occurs in 1 CellFix (BD Biosciences) for 10 min at room
temperature and the cells were permeabilized with Perm2 (BD
Biosciences) for 10 min at room temperature. Finally, the cells
were fixed in 1 CellFix (BD Biosciences). Data were obtained
on a CyAnTM ADP LX9 flow cytometer and analyzed using the
summit 4.2. software (DakoCytomation).
RNA purification and quantitative real-time RT-PCR
mRNA were extracted from purified pDC (>95%) using the
MagNa Pure LC mRNA Isolation Kit following manufacturer's
instructions (Roche Diagnostics, Brussels, Belgium). RT and
real-time PCR were then carried out using LightCycler-RNA
Master Hybridization Probes (one-step procedure) on a
Lightcycler device (Roche Diagnostics). Primers and sequences
are listed in Supporting Information Table 3.
Microarray experiments
RNA preparation
pDC from three adult and three cord blood donors were left
untreated or stimulated with R-848 (10 lg/mL) for 2 h. The
RNAwas isolated using TRIzol reagent (Invitrogen,Merelbeke,
Belgium) and RNAeasy Micro Kit (Qiagen, The Netherlands).
Affymetrix GeneChip hybridization
The RNA quality was checked with an Agilent 2100 Bioana-
lyzer (Agilent Technologies, Palo Alto, CA). All RNA used in
our experiments present the quality criteria defined by Agilent,
and processed according to Affymetrix's instructions. Briefly,
150 ng of total RNA were reverse-transcribed using a
T7-(dT) 24 primer and Superscript II reverse transcriptase.
Double-stranded cDNA was synthesized and purified with
GeneChipJ Sample Cleanup Modules. cRNA was then synthe-
sized using the Megascript T7 kit (Ambion) and purified. Six-
hundred nanograms of this cRNA was reverse-transcribed
using random hexamer primers, and Superscript II RT and
double-stranded cDNA was subsequently synthesized and
purified. Biotinylated cRNA was synthesized from the double-
stranded cDNA using T7 RNA polymerase and a biotin-
conjugated pseudo-uridine containing nucleotide mixture
provided in the Affymetrix kit.
Prior to hybridization, the cRNA was purified and
fragmented. Fifteen micrograms of each experimental sample
and 15 lg of each Affymetrix eukaryotic hybridization control
were hybridized for 16 h to human U133 Plus 2.0 GeneChips.
Arrays were washed and stained with streptavidin-PE
(Molecular Probes, Eugene, OR), biotinylated anti-streptavidin
(Vector Laboratories, Burlingame, CA) and scanned with an
Affymetrix GeneChipJ Scanner 3000. The Affymetrix eukar-
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yotic hybridization control kit and Poly-A RNA control kit were
used to ensure efficiency of hybridization and cRNA amplifica-
tion. All cRNAwere synthesized at the same time. Experiments
were done by DNAVisionJ (Gosselies, Belgium). Array images
(“.DAT” files) were visually screened to discount for signal
artefacts, scratches or debris and Affymetrix quality metrics
were analyzed.
Data analysis
Various Bioconducter (www.bioconducter.org) packages for R
(http://www.r-project.org) were used for data analysis. In
brief, the Simpleaffy package was used to pre-process the data
using the RMA algorithm [31]. Differentially expressed genes
were identified using linear models and empirical Bayesian
methods [32] as implemented in the LIMMA package.
Three statistical approaches, all part of BioConductor
software, were used to identify differentially expressed genes:
(1) significance of analysis for microarrays [33], (2) a paired
t-test controlling the false discovery rate using Benjamini and
Hochberg correction [34], (3) the moderated t-test in linear
models for microarray data [32] also enconcompassing the
Benjamini and Hochberg correction. Data were first filtered
based on “MA plot”, where M = log2(fluorescent dye intensity
of infected DC/uninfected DC) and A = log2Hfluorescent dye
intensity of (treated pDC)  (untreated pDC), as described by
Yang et al. [35] for cDNA microarray. In the analysis between
treated and untreated pDC or untreated adult versus cord
blood pDC, a gene was called differentially expressed if the
M value was more than 2 (up-regulated) or less than –2
(down-regulated) and the p value was less or equal to 0.001. A
gene is called differentially regulated between adult pDC and
cord blood pDC if the M value was more than 1 or less than –1
and the p value was less or equal to 0.05.
Determination of nuclear translocation using the
ImageStream
pDCwere enriched from PBMC or CBMC by negative depletion
as described above. Autologous PBMC or CBMC were added
back to the enriched pDC fraction to reach the number of
2106 cells per condition. Cells were stimulated for the
indicated time with CpG A (10 lg/mL) or HSV-1 (MOI 1) at
37C. After incubation, cells were surface-stained with both
anti-BDCA-2-PE and anti-BDCA-4-PE antibodies, fixed in 1%
formaldehyde and stored overnight at 4C. The following day,
samples were permeabilized with 0.1% Triton in 1 PBS and
incubated with anti-IRF-7 or anti-NF-jB (p65) antibodies
(SantaCruz Biotechnology, Santa Cruz, CA) 30 min at room
temperature. For the secondary antibodies, goat anti-rabbit
IgG-FITC (Jackson Immunoresearch, Suffolk, UK) was added
and the cells were incubated for 15 min at room temperature.
Following washing, cells were fixed in 1% formaldehyde and
shipped to Amnis. Nuclei were stained with DRAQ5 immedi-
ately before acquisition. Samples were acquired using the
ImageStream imaging flow cytometer. Images were captured
in five channels: darkfield, brightfield, FITC, PE and DRAQ5,
and analyzed using IDEAS software (Amnis) as recently
described [9].
Briefly, single BDCA-2/4+ cells were gated and then
analyzed for nuclear translocation of IRF-7 or NF-jB using
similarity scoring of the transcription factor and DRAQ5 image
pair on a per-cell basis. The similarity score is a log-
transformed Pearson's correlation coefficient of the pixel
values of the DRAQ5 and transcription factor images. If the
transcription factor is nuclear-localized within a cell, the two
images will appear similar and the cell will have a large positive
value.
Statistical analysis
Data were compared using unpaired Mann–Whitney U–test.
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